| Nhc Homecare Springfield | |
| 506 Northcrest Drive, Springfield, Tennessee 37172 | |
| (615) 384-0687 | |
| Name | Nhc Homecare Springfield |
|---|---|
| Location | 506 Northcrest Drive, Springfield, Tennessee |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 447276 |
| Ownership Type | Voluntary Non-profit - Private |
| Service Area Zip Codes | 37010, 37015, 37022, 37031, 37032, 37035, 37040, 37042, 37043, 37048, 37049, 37066, 37072, 37073, 37075, 37076, 37080, 37083, 37115, 37122, 37138, 37141, 37146, 37148, 37150, 37172, 37186, 37188, 37189, 37191, 37203, 37206, 37207, 37208, 37210, 37211, 37214, 37216, 37217, 37218, 37228 |
| NPI Number | 1255356143 |
| Organization Name | NHC-OP LP |
| Address | 2100 Park Plaza Dr, Springfield, TN 37172 |
| Phone Number | 615-384-0687 |
News Archive
PATIENTS living with a poorly understood chronic voice disorder which causes involuntary muscle spasms, impairing speech and swallowing, can now receive treatment nearer to home thanks to the launch of a specialist multidisciplinary clinic at Sheffield Teaching Hospitals NHS Foundation Trust.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal.
Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 4 days ago
| Quality Rating: |
News Archive
PATIENTS living with a poorly understood chronic voice disorder which causes involuntary muscle spasms, impairing speech and swallowing, can now receive treatment nearer to home thanks to the launch of a specialist multidisciplinary clinic at Sheffield Teaching Hospitals NHS Foundation Trust.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal.
Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 97.8 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 98.7 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.9 | 99.6 |
| How often the home health team checked patients for depression | 98.2 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 82.6 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 85.6 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 98.3 | 96.4 |
News Archive
PATIENTS living with a poorly understood chronic voice disorder which causes involuntary muscle spasms, impairing speech and swallowing, can now receive treatment nearer to home thanks to the launch of a specialist multidisciplinary clinic at Sheffield Teaching Hospitals NHS Foundation Trust.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal.
Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 77.1 | 79.6 |
| How often patients got better at getting in and out of bed | 79.8 | 81.1 |
| How often patients got better at bathing | 81.9 | 82.3 |
| How often patients’ breathing improved | 78.6 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 92.2 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 69.3 | 75 |
| How often home health patients had to be admitted to the hospital | 17.6 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 12.4 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 98.7 | 94 |
News Archive
PATIENTS living with a poorly understood chronic voice disorder which causes involuntary muscle spasms, impairing speech and swallowing, can now receive treatment nearer to home thanks to the launch of a specialist multidisciplinary clinic at Sheffield Teaching Hospitals NHS Foundation Trust.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal.
Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 4 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
PATIENTS living with a poorly understood chronic voice disorder which causes involuntary muscle spasms, impairing speech and swallowing, can now receive treatment nearer to home thanks to the launch of a specialist multidisciplinary clinic at Sheffield Teaching Hospitals NHS Foundation Trust.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal.
Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 4 days ago
The patient survey data of Nhc Homecare Springfield is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 92 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 90 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 85 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 88 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 82 | 78 |
News Archive
PATIENTS living with a poorly understood chronic voice disorder which causes involuntary muscle spasms, impairing speech and swallowing, can now receive treatment nearer to home thanks to the launch of a specialist multidisciplinary clinic at Sheffield Teaching Hospitals NHS Foundation Trust.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug, Adva-27a, beginning with GMP manufacturing and animal tox studies.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal.
Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).
Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 4 days ago
Nhc Homecare Springfield Location: 506 Northcrest Drive, Springfield, Tennessee 37172 Ratings: Phone: (615) 384-0687 | |
Lifeline Home Health Care Location: 2109 Park Plaza Suite 200, Springfield, Tennessee 37172 Ratings: Phone: (615) 384-4644 |